A translational study including samples from two randomized neoadjuvant GBG trials (GeparTrio and GeparQuattro) that aimed to evaluate a novel test (mEPclin) for predicting the risk of distance recurrence after neoadjuvant chemotherapy in patients with residual estrogen receptor (ER)-positive/HER2-negative breast cancer has been published in the Clinical Cancer Research.
Identifying patients who require additional therapy after neoadjuvant chemotherapy (NACT) is of increasing clinical relevance in patients with luminal-like BC as many new treatment options for these patients are available or in development. In this study, a modified EPclin test (mEPclin), a novel combination of post-neoadjuvant EndoPredict (EP) risk score, pathological tumor size and nodal status, seems to be able to identify a cohort of patients with ER-positive/HER2-negative breast cancer at high risk for relapse after NACT which might benefit from additional post-neoadjuvant therapies.
Loibl S, Weber K, Huober J, Krappmann K, Marmé F, Schem C, Engels K, Pfitzner BM, Kümmel S, Furlanetto J, Hartmann A, Darb-Esfahani S, Müller V, Staebler A, von Minckwitz G, Kronenwett R, Denkert C. Risk assessment after neoadjuvant chemotherapy in luminal breast cancer using a clinico-molecular predictor. Clin Cancer Res. 2018, 15;24:3358-3365.
Link in PubMed